Overview

Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

Status:
Not yet recruiting
Trial end date:
2024-04-15
Target enrollment:
Participant gender:
Summary
Multi-center, randomized, double-blind, placebo-controlled, 6- month study in subjects with mild to moderate Dementia with Lewy Bodies.
Phase:
Phase 2
Details
Lead Sponsor:
Cognition Therapeutics
Collaborator:
National Institute on Aging (NIA)